Loading clinical trials...

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE3

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition

NCT07184385•StemCyte, Inc.

View on ClinicalTrials.gov

Summary

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Detailed Description

This is a two-arm, multi-center, double-blind, randomized, placebo-controlled phase III study. A total of 60 subjects with post-COVID will be enrolled.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female aged ≥ 18
•With post-COVID condition
•Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
•Able to provide signed informed consent (by the subject or his/her legally authorized representative)
•Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent

Exclusion Criteria

•Neurological disorders prior to COVID-19 diagnosis
•With pre-existing terminal illness
•With known immune disease
•Is pregnant or breastfeeding
•Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening
•Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period
•Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases
•Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

Key Dates

Start Date

March 31, 2026

Primary Completion Date

June 30, 2027

Completion Date

September 30, 2027

Last Updated

September 23, 2025

Enrollment

ESTIMATED participants

Conditions

Long COVIDPost-COVID-19 ConditionPost-COVID SyndromePost-COVID Condition

Interventions

REGENECYTE

BIOLOGICAL

Placebo

BIOLOGICAL

Contacts

Ernest Lau, MS

CONTACT

886-2-26013013 Sct_pCOV02@stemcyte.com.tw

Taurine Supplementation in Long COVID

NCT06721949

Long COVID

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

RECRUITINGPHASE3

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Inclusion Criteria

Exclusion Criteria

Taurine Supplementation in Long COVID

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Presynaptic Imaging in Major Depressive Episodes After COVID-19

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome